@entity167 screening scores and the risk of new-onset XXXX or related hospitalization.

@entity1 @entity788 @entity167 @entity409 @entity344 @entity360
BACKGROUND: Excessive @entity167 use is associated with a variety of negative health outcomes, including @entity409 , @entity360 , and @entity788 . OBJECTIVE: To determine the 2-year risk of gastrointestinal-related hospitalization and new-onset @entity344 based on @entity167 screening scores. DESIGN: Retrospective cohort study. @entity1 : Male (N = 215, 924) and female (N = 9,168) outpatients who returned mailed questionnaires and were followed for 24 months. MEASUREMENTS: @entity167 Use Disorder Identification Test-Consumption Questionnaire (AUDIT-C), a validated three-item @entity167 screening questionnaire (0-12 points). RESULTS: Two-year risk of hospitalization with a @entity344 was increased in @entity1 with AUDIT-C scores of 5-8 and 9-12 (OR 1.54, 95% CI = 1.27-1.86; and OR 3.27; 95% CI = 2.62-4.09 respectively), and @entity1 with AUDIT-C scores of 9-12 (OR 6.84, 95% CI = 1.85 - 25.37). @entity1 with AUDIT-C scores of 5-8 and 9-12 had increased risk of new-onset @entity409 (OR 1.49, 95% CI = 1.30-1.71; and OR 2.82, 95% CI = 2.38-3.34 respectively), and new-onset of @entity360 (OR 1.28, 95% CI = 1.05-1.57; and OR 2.14, 95% CI = 1.54-2.97 respectively). Two-year risk of new-onset @entity788 in @entity1 with AUDIT -C scores 9-12 was also increased (OR 2.14; 95% CI = 1.54-2.97). CONCLUSIONS: Excessive @entity167 use as determined by AUDIT-C is associated with 2-year increased risk of gastrointestinal-related hospitalization in @entity1 and @entity1 and new-onset @entity409 , @entity360 , and @entity788 in @entity1 . These results provide risk information that clinicians can use in evidence-based conversations with @entity1 about their @entity167 consumption.
